JP2003510286A - 糖尿病性腎症および微量アルブミン尿症の治療 - Google Patents

糖尿病性腎症および微量アルブミン尿症の治療

Info

Publication number
JP2003510286A
JP2003510286A JP2001526191A JP2001526191A JP2003510286A JP 2003510286 A JP2003510286 A JP 2003510286A JP 2001526191 A JP2001526191 A JP 2001526191A JP 2001526191 A JP2001526191 A JP 2001526191A JP 2003510286 A JP2003510286 A JP 2003510286A
Authority
JP
Japan
Prior art keywords
individual
diabetic
salviemyl
herb
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001526191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510286A5 (https=
Inventor
リー，ハイ−リ
リー，ヒュン，チュル
ジャン，マンキル
シャー，サドヒル，ブイ．
Original Assignee
シヴァ バイオメディカル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シヴァ バイオメディカル，エルエルシー filed Critical シヴァ バイオメディカル，エルエルシー
Publication of JP2003510286A publication Critical patent/JP2003510286A/ja
Publication of JP2003510286A5 publication Critical patent/JP2003510286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001526191A 1999-09-29 2000-09-21 糖尿病性腎症および微量アルブミン尿症の治療 Pending JP2003510286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/408,436 1999-09-29
US09/408,436 US6149915A (en) 1999-09-29 1999-09-29 Treatment of diabetic nephropathy and microalbuminuria
PCT/US2000/025783 WO2001022981A1 (en) 1999-09-29 2000-09-21 Treatment of diabetic nephropathy and microalbuminuria

Publications (2)

Publication Number Publication Date
JP2003510286A true JP2003510286A (ja) 2003-03-18
JP2003510286A5 JP2003510286A5 (https=) 2007-11-08

Family

ID=23616291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526191A Pending JP2003510286A (ja) 1999-09-29 2000-09-21 糖尿病性腎症および微量アルブミン尿症の治療

Country Status (7)

Country Link
US (3) US6149915A (https=)
EP (1) EP1218020A1 (https=)
JP (1) JP2003510286A (https=)
CN (1) CN1387439A (https=)
AU (1) AU771275B2 (https=)
CA (1) CA2386000A1 (https=)
WO (1) WO2001022981A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517025A (ja) * 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
WO2007102451A1 (ja) * 2006-03-07 2007-09-13 Nippon Shinyaku Co., Ltd. 育毛剤
US8029829B2 (en) 2005-02-03 2011-10-04 Taiyo Kagaku Co., Ltd. Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy
JP2017510592A (ja) * 2014-04-01 2017-04-13 シャンハイ・インスティチュート・オブ・マテリア・メディカ・チャイニーズ・アカデミー・オブ・サイエンシズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ，Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 高純度のリトスペルミン酸ｂマグネシウム及びその製造方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
CN100341581C (zh) * 2005-07-29 2007-10-10 上海第二医科大学附属第九人民医院 一种丹酚酸b有效干预口腔癌动物模型的方法
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
WO2008117901A1 (en) 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University A method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
US9345732B2 (en) 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
CN102550916A (zh) * 2012-02-04 2012-07-11 王姗思 一种用于糖尿病肾病的食品
CN102614267A (zh) * 2012-04-24 2012-08-01 许风国 一种治疗糖尿病肾病的中药组合物及其制备方法
CN103830496A (zh) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 一种辅助降糖的组合物
CN104547498A (zh) * 2014-12-31 2015-04-29 黎细乐 一种中药组合物的新用途
US20160361288A1 (en) * 2015-06-10 2016-12-15 Postech Academy-Industry Foundation Pharmaceutical compositions for preventing or treating diabetic nephropathy comprising the activity inhibitor of tenc1
CN105311413A (zh) * 2015-11-18 2016-02-10 暨南大学 治疗糖尿病肾病的含有艾叶的中药组合物及其制备方法
CN107551172A (zh) * 2017-10-26 2018-01-09 马雪英 一种治疗肾病综合症的药物及其制备方法
CN110215449A (zh) * 2019-05-13 2019-09-10 中国科学院长春应用化学研究所 紫草酸在抑制胰岛素淀粉样多肽聚集中的应用
CN112190646B (zh) * 2020-11-19 2021-12-28 首都医科大学附属北京中医医院 一种治疗糖尿病肾病的中药组合物及其制备方法
CN112569313B (zh) * 2020-12-28 2022-02-22 贵州三力制药股份有限公司 治疗肾病的中药组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268682A (ja) * 1988-04-21 1989-10-26 Minofuaagen Seiyaku Honpo:Goushi 腎機能改善剤及びリソスペルミン酸塩の製造方法
JPH0748403A (ja) * 1993-06-03 1995-02-21 Nippon Chem Res Kk 丹参由来多糖類、その製造法および用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358962A (en) * 1993-04-22 1994-10-25 Minophagen Pharmaceutical Company Antihypertensive method
JP3638967B2 (ja) * 1993-06-03 2005-04-13 日本ケミカルリサーチ株式会社 ネフローゼ症候群及び肝障害症状の寛解剤
US5547945A (en) * 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268682A (ja) * 1988-04-21 1989-10-26 Minofuaagen Seiyaku Honpo:Goushi 腎機能改善剤及びリソスペルミン酸塩の製造方法
JPH0748403A (ja) * 1993-06-03 1995-02-21 Nippon Chem Res Kk 丹参由来多糖類、その製造法および用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOKOZAWA T. ET AL: "Effects of a Dan Shen component, magnesium lithospermate B, in nephrectomized rats", 日本腎臓学会誌, vol. 37, no. 2, JPN6011005042, 1995, pages 105 - 111, ISSN: 0001842417 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517025A (ja) * 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
US8029829B2 (en) 2005-02-03 2011-10-04 Taiyo Kagaku Co., Ltd. Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy
WO2007102451A1 (ja) * 2006-03-07 2007-09-13 Nippon Shinyaku Co., Ltd. 育毛剤
JPWO2007102451A1 (ja) * 2006-03-07 2009-07-23 日本新薬株式会社 育毛剤
JP2017510592A (ja) * 2014-04-01 2017-04-13 シャンハイ・インスティチュート・オブ・マテリア・メディカ・チャイニーズ・アカデミー・オブ・サイエンシズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ，Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 高純度のリトスペルミン酸ｂマグネシウム及びその製造方法

Also Published As

Publication number Publication date
AU771275B2 (en) 2004-03-18
CA2386000A1 (en) 2001-04-05
US20020025347A1 (en) 2002-02-28
EP1218020A1 (en) 2002-07-03
WO2001022981A1 (en) 2001-04-05
AU4023501A (en) 2001-04-30
US6267992B1 (en) 2001-07-31
US6149915A (en) 2000-11-21
CN1387439A (zh) 2002-12-25

Similar Documents

Publication Publication Date Title
JP2003510286A (ja) 糖尿病性腎症および微量アルブミン尿症の治療
AU2016246524B2 (en) Pharmaceutical compositions for combination therapy
Hu et al. Effects and mechanism of Ganoderma lucidum polysaccharides in the treatment of diabetic nephropathy in streptozotocin‐induced diabetic rats
JP2018184441A (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
Zhu et al. Rehmannia glutinosa Libosch and Cornus officinalis Sieb herb couple ameliorates renal interstitial fibrosis in CKD rats by inhibiting the TGF-β1/MAPK signaling pathway
Diao et al. Potential therapeutic activity of berberine in thyroid-associated ophthalmopathy: inhibitory effects on tissue remodeling in orbital fibroblasts
US20080279843A1 (en) Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
CN107349244B (zh) 丙二酰基人参皂苷的提取方法
CN102631358A (zh) 虎杖苷在制备糖尿病肾病治疗药物中的应用
Sweeney et al. Regulation of the Na, K-pump by leptin in 3T3-L1 fibroblasts
US20240156889A1 (en) A method for reducing animal weight
CN117942332A (zh) 鼠尾草酚在制备治疗或缓解顺铂诱导的急性肾损伤的药物中的应用
US10172903B2 (en) Composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof
CN105687194B (zh) 一种cb2受体激动剂的药物用途
CN106727732B (zh) 蛹虫草提取物及其制备方法和应用
Wu et al. Clerodendranthus spicatus-Cordyceps cicadae regulates mitophagy and protects renal tubular epithelial cells from hyperuricemic nephropathy
CN118436718B (zh) 一种荔枝核提取物及其制备方法和应用
CN113456684B (zh) 滨蒿用于制备治疗肺纤维化的药物的用途
Zhao et al. The Effect of Fanshi Tongfeng Fang on Hyperuricemia-Induced Apoptosis and Inflammation
CN103432202B (zh) 一种从半枝莲中提取降糖物质的方法及其应用
US20250017907A1 (en) Method for preventing and/or treating liver fibrosis by using 6-methoxybenzoxazolinone and coix lachryma-jobi l. extract comprising 6-methoxybenzoxazolinone
CN121754580A (zh) 香青兰提取物在高原性红细胞增多症药物中的应用
WANG et al. Shenshuaining Tablet combined with dapagliflozin in the treatment of stage Ⅲ-Ⅳ diabetic kidney disease
RU2691404C2 (ru) Композиция, содержащая сцирпусин а и сцирпусин в, и ее потенциал в качестве средства против ожирения
CN121588093A (zh) 达格列净在制备用于预防和/或治疗肥胖相关盐敏感性高血压的药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111109